National Pension Service Acquires 360,392 Shares of Cencora, Inc. $COR

National Pension Service grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 119.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 662,374 shares of the company’s stock after buying an additional 360,392 shares during the quarter. National Pension Service’s holdings in Cencora were worth $198,613,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Cencora in the 1st quarter valued at approximately $28,000. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Cencora in the 1st quarter worth approximately $39,000. Hantz Financial Services Inc. boosted its holdings in shares of Cencora by 712.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Cencora during the 2nd quarter valued at approximately $61,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.4%

Shares of COR opened at $363.75 on Thursday. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $366.17. The company has a 50-day moving average of $318.52 and a 200 day moving average of $301.12. The firm has a market capitalization of $70.52 billion, a price-to-earnings ratio of 37.42, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wells Fargo & Company raised their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, TD Cowen raised their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $371.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.